Abstract
Abnormal excitation–contraction coupling is a key pathophysiologic component of heart failure (HF), and at a molecular level reduced expression of the sarcoplasmic reticulum (SR) Ca2+ ATPase (SERCA2a) is a major contributor. Previous studies in small animals have suggested that restoration of SERCA function is beneficial in HF. Despite this promise, the means by which this information might be translated into potential clinical application remains uncertain. Using a recently established cardiac-directed recirculating method of gene delivery, we administered adeno-associated virus 2 (AAV2)/1SERCA2a to sheep with pacing-induced HF. We explored the effects of differing doses of AAV2/1SERCA2a (low 1 × 1010 d.r.p.; medium 1 × 1012 d.r.p. and high 1 × 1013 d.r.p.) in conjunction with an intra-coronary delivery group (2.5 × 1013 d.r.p.). At the end of the study, haemodynamic, echocardiographic, histopathologic and molecular biologic assessments were performed. Cardiac recirculation delivery of AAV2/1SERCA2a elicited a dose-dependent improvement in cardiac performance determined by left ventricular pressure analysis, (+d P/d tmax; low dose −220±70, P>0.05; medium dose 125±53, P<0.05; high dose 287±104, P<0.05) and echocardiographically (fractional shortening: low dose −3±2, P>0.05; medium dose 1±2, P>0.05; high dose 6.5±3.9, P<0.05). In addition to favourable haemodynamic effects, brain natriuretic peptide expression was reduced consistent with reversal of the HF molecular phenotype. In contrast, direct intra-coronary infusion did not elicit any effect on ventricular function. As such, AAV2/1SERCA2a elicits favourable functional and molecular actions when delivered in a mechanically targeted manner in an experimental model of HF. These observations lay a platform for potential clinical translation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002; 8: 864–871.
Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 2002; 105: 602–607.
Kawada T, Nakazawa M, Nakauchi S, Yamazaki K, Shimamoto R, Urabe M et al. Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc Natl Acad Sci USA 2002; 99: 901–906.
del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999; 100: 2308–2311.
Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99: e3–e9.
Muller OJ, Katus HA, Bekeredjian R . Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007; 73: 453–462.
Hasenfuss G, Pieske B . Calcium cycling in congestive heart failure. J Mol Cell Cardiol 2002; 34: 951–969.
Hajjar RJ, Kang JX, Gwathmey JK, Rosenzweig A . Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 1997; 95: 423–429.
del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 2001; 104: 1424–1429.
Kaye D, Preovolos A, Marshall T, Byrne M, Hoshijima M, Hajjar R et al. percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007; 50: 253–260.
Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000; 97: 793–798.
Teucher N, Prestle J, Seidler T, Currie S, Elliott EB, Reynolds DF et al. Excessive sarcoplasmic/endoplasmic reticulum Ca2+-ATPase expression causes increased sarcoplasmic reticulum Ca2+ uptake but decreases myocyte shortening. Circulation 2004; 110: 3553–3559.
Muller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006; 70: 70–78.
Mah C, Cresawn KO, Fraites Jr TJ, Pacak CA, Lewis MA, Zolotukhin I et al. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Therapy 2005; 12: 1405–1409.
Inagaki K, Fuess S, Storm TA, Gibson GA, McTiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45–53.
Chu D, Sullivan CC, Weitzman MD, Du L, Wolf PL, Jamieson SW et al. Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors. J Thorac Cardiovasc Surg 2003; 126: 671–679.
French BA, Mazur W, Geske RS, Bolli R . Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 1994; 90: 2414–2424.
Periasamy M, Reed TD, Liu LH, Ji Y, Loukianov E, Paul RJ et al. Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene. J Biol Chem 1999; 274: 2556–2562.
Muhlhauser J, Jones M, Yamada I, Cirielli C, Lemarchand P, Gloe TR et al. Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. Gene Therapy 1996; 3: 145–153.
Donahue JK, Kikkawa K, Johns DC, Marban E, Lawrence JH . Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci USA 1997; 94: 4664–4668.
Donahue JK, Kikkawa K, Thomas AD, Marban E, Lawrence JH . Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Therapy 1998; 5: 630–634.
Wright MJ, Wightman LM, Latchman DS, Marber MS . In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo. Gene Therapy 2001; 8: 1833–1839.
Hayase M, Del Monte F, Kawase Y, Macneill BD, McGregor J, Yoneyama R et al. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol 2005; 288: H2995–H3000.
Raake PW, Hinkel R, Muller S, Delker S, Kreuzpointner R, Kupatt C et al. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Therapy 2008; 15: 12–17.
Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 2002; 99: 11363–11368.
Acknowledgements
This work was supported in part by funding granted by Celladon Corporation, La Jolla, CA, USA, and in part by grants from the National Institutes of Health: R01 HL078691, HL057263, HL071763, HL080498, HL083156 and a Leducq Transatlantic Network (RJH).
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosure
Dr John M Power and Dr David M Kaye are inventors of the V-Focus cardiac recirculation system. Dr Roger Hajjar is a co-founder of Celladon Corporation.
Rights and permissions
About this article
Cite this article
Byrne, M., Power, J., Preovolos, A. et al. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 15, 1550–1557 (2008). https://doi.org/10.1038/gt.2008.120
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2008.120
Keywords
This article is cited by
-
Cardiomyocyte-targeting exosomes from sulforaphane-treated fibroblasts affords cardioprotection in infarcted rats
Journal of Translational Medicine (2023)
-
Mechanisms underlying pathological Ca2+ handling in diseases of the heart
Pflügers Archiv - European Journal of Physiology (2021)
-
Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL
Gene Therapy (2020)
-
Analysis of recombinant adeno-associated viral vector shedding in sheep following intracoronary delivery
Gene Therapy (2019)
-
Comprehensive cardiac phenotyping in large animals: comparison of pressure–volume analysis and cardiac magnetic resonance imaging in pig post-myocardial infarction systolic heart failure
The International Journal of Cardiovascular Imaging (2019)